MGNX
ANALYST COVERAGE22 analysts
BUY
+30.4%upside to target
Buy
1255%
Hold
941%
Sell
15%
12 Buy (55%)9 Hold (41%)1 Sell (4%)
Full report →
Key MetricsTTM
Market Cap$292.39M
Revenue TTM$157.08M
Net Income TTM-$70.36M
Free Cash Flow-$71.69M
Gross Margin69.9%
Operating Margin-40.5%
Net Margin-44.8%
Return on Equity-147.8%
Return on Assets-32.3%
Debt / Equity1.72
Current Ratio1.90
EPS TTM$-1.11
PRICE
Prev Close
4.24
Open
4.46
Day Range4.36 – 4.64
4.36
4.64
52W Range1.19 – 4.64
1.19
4.64
99% of range
VOLUME & SIZE
Avg Volume
1.3M
FUNDAMENTALS
P/E Ratio
-4.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.64
High vol
TECHNICAL
RSI (14)
87
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 96 days
Aug 26

MGNX News

About

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Scott Koenig
James KarrelsSenior Vice President, Chief Financial Officer & Corporate Secretary
Jeffrey Stuart PetersSenior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer
Harish KrishnaswamySenior Vice President of Business Development & Portfolio Planning
Beth SmithVice President, Controller & Treasurer
Eric Blasius RisserChief Executive Officer, President & Director
Ezio BonviniSenior Vice President of Research & Chief Scientific Officer
Frank George Perabo FEBUVice President & Interim Head of Clinical Development
Thomas SpitznagelSenior Vice President of Technical Operations
Steve HarigSenior Vice President of Human Resources